393
Views
17
CrossRef citations to date
0
Altmetric
Research Articles

On Topological Indices of Remdesivir Compound Used in Treatment of Corona Virus (COVID 19)

, ORCID Icon, , ORCID Icon, , & show all
Pages 4300-4316 | Received 16 Dec 2020, Accepted 02 Feb 2021, Published online: 19 Feb 2021
 

Abstract

Corona virus cause diseases ranging from the common cold to Severe Acute Respiratory Syndrome (SARS). Several therapeutic agents have been evaluated for the treatment of Covid-19, but none have yet been shown to be efficacious. Remdesivir Gilead Sciences number (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with inhibitory activity against SARS-CoV and the Middle East respiratory syndrome (MERS-CoV), was identified early as a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 invitro. Knowledge about the potential efficacy of Remdesivir against corona viruses has been restricted to in vitro studies and animal models. However, information related to COVID-19 is rapidly growing. Several clinical trials are ongoing for the management of COVID-19 using Remdesivir. Efficacy of Remdesivir (GS-5734) against Ebola virus has been demonstrated. In the field of Medical Science, concerning the definition of the topological index on the molecular structure and corresponding medical, biological, chemical, pharmaceutical properties of drugs can be studied by the topological index calculation. In this paper, we compute some reverse topological indices namely, the reverse general Randic index, the reverse atom bond connectivity index, the reverse geometric arithmetic index, the reverse forgotten index, the reverse Balaban index and the reverse Zagreb type indices.

Conflicts of interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Funding

This research work of the first author was sponsored by the Shandong Provincial Natural Science Foundation, China (ZR2018MA010)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.